10/28/2022 6:45:35 AM
DaVita Inc. (DVA) Has Lowered Its FY22 EPS Estimate To 6.20 - 6.70 From 7.50 - 8.50
10/28/2022 6:31:45 AM
DaVita Q3 EPS $1.13 And Adj EPS $1.45
9/13/2022 5:03:09 PM
DaVita Appoints Adam Schechter To Its Board Of Directors
8/1/2022 4:18:47 PM
DaVita Q2 EPS $2.30 Vs. $2.64 Year Ago
5/26/2022 6:46:23 AM
Medtronic And DaVita Intent To Form Independent Kidney Care-focused Medical Device Company
5/5/2022 4:12:13 PM
DaVita Q1 EPS $1.61 Vs. $2.09 Year Ago
3/1/2022 6:27:05 AM
Pathalys Pharma Acquires License To EA Pharma's Upacicalcet Worldwide Outside Of Japan And Asia
2/17/2022 6:07:02 AM
DaVita Clinical Research Study Finds Efficacy Of Common COVID-19 Vaccines At Parity For Kidney Patients
2/16/2022 6:04:59 AM
DaVita Kidney Care Appoints Mihran Naljayan As Chief Medical Officer (CMO) Of Home Modalities
2/10/2022 4:07:40 PM
DaVita Q4 EPS $1.79 Vs. $1.5 0 Year Ago
1/18/2022 6:09:36 AM
DaVita Announces Acquisition Of MedSleuth